AfterRaise/Companies/Cloverleaf Bio

Cloverleaf Bio

$33M SeedRaised yesterdayNew Haven, USABiotech & PharmaUSA
Visit website →

Why now

Where Cloverleaf Bio is today

Cloverleaf Bio announced a funding round of $33M on 8 September 2026, led by 4BIO Capital.

Latest round
Seed
Amount
$33M
Announced
8 September 2026
Headquarters
New Haven, USA
Sector
Biotech & Pharma
Investors
4BIO Capital
Also participating
AbbVie Ventures, Eli Lilly and Company, Boehringer Ingelheim Venture Fund, Draper Associates, Mission BioCapital, and American Cancer Society BrightEdge
Relevant leadership
CEO Austin Draycott

Momentum AfterRaise intelligence

AfterRaise Score

66
Building momentum
1 funding signal in the last 90 days
Funding recency
40/40
announced within the last 30 days
Round scale
16/25
round size relative to the market
Funding stage
10/20
Seed
Funding cadence
0/15
one funding event tracked this year
Arriving with the signals layer
  • Hiring momentum Open roles and hiring pace
  • Market expansion New offices and new countries
  • Leadership Executive appointments
  • Product activity Launches and releases

In their own words

What Cloverleaf Bio says it is doing

Work here? Reserve your page

Public signal Described in the funding announcement as "provider of engineered transfer RNA (tRNA) based payloads for cancer". Source

Research and development

Public signal Read from the company's own description of what the funding supports.

Since the raise

What has happened since

  • 8 September 2026
    $33M Seed
    Led by 4BIO Capital.

Public signal The timeline currently holds funding events, because those are the signals AfterRaise observes today. Hiring, leadership, expansion and product events join it with the signals layer.

What may happen next

What this raise could create

AfterRaise intelligenceNot a statement of fact

What may happen next

  • Research programme expansion
  • Scientific team growth
  • Accelerated hiring across functions
  • Founding team growth

Opportunities this could create

  • Clinical operations
  • Scientific hiring
  • Scientific advisers
  • Research operations
  • Specialist suppliers

Based on the Biotech & Pharma sector, a Seed round and the priorities the company itself set out. Not a statement of fact.

Medium momentum2 connected signals
  • 8 September 2026$33M Seed announced
  • 8 September 2026Stated priority: research and development

High momentum means several meaningful company changes have occurred in a short period. Signals here are funding events and the priorities the company stated; hiring, leadership and expansion detection join with the signals layer.

Open to

What Cloverleaf Bio is open to

Not yet specified

Cloverleaf Bio has not told AfterRaise which approaches it welcomes. Until it does, we do not assume. Offers to help are held and shown to the company, and the company decides whether to open a conversation.

Work here? Set your preferences

Opportunities

Ways to work with Cloverleaf Bio

No open opportunities listed

Jobs, projects, partnerships, advisory and supplier needs appear here once the company has claimed its page and published them, and any role we read from its own job board appears automatically.

Work here? Open the first one

Helpful contributors

People who have contributed here

Nobody yet

When someone offers help and the company says it was useful, they appear here. Reputation on AfterRaise is built from contributions the company confirmed, not from follower counts.

Do you work at Cloverleaf Bio?

Reserve your company page.

This page was created from publicly available information. When verified company accounts open, your team will be able to correct your profile, tell the market what you actually need and control how people approach you.

What we do not have yet: the roles and projects you have open. Claiming the page is how you fill those in.

Someone else requesting access does not give them ownership. Every company administrator is verified before access is granted.

Join the first 500 verified companies to receive Founding Company status.

Also moving

Other Biotech & Pharma companies

See the sector